Arbutus Q1 net income $169.7M ($0.88/share) on $179.1M revenue from Moderna settlement

Arbutus Biopharma Corp

2026-Q1 EPS reported $0.87 revenue$179,126,000

Revenue $179.1M up from $1.8M YoY; $178.7M license revenue from Genevant related to Moderna settlement.
Net income $169.7M vs net loss $24.5M in Q1 2025; diluted EPS $0.87.
Moderna settlement: $950M noncontingent payment due July 2026; Arbutus expects ~$178.7M.
Cash, equivalents and marketable securities $95.2M as of March 31, 2026.
FDA granted Fast Track designation for imdusiran for chronic hepatitis B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

Arbutus Biopharma Corp reported first quarter ended March 31, 2026 results: revenue $179.1 million, net income $169.7 million, EPS income of $0.88 per basic and $0.87 per diluted common share.

Period: first quarter ended March 31, 2026
Revenue: $179.1 million
Net income: $169.7 million
EPS: income of $0.88 per basic and $0.87 per diluted common share
Result: reported results

Exact text from the filing

Revenue Total revenue was $179.1 million for the quarter ended March 31, 2026, compared to $1.8 million for the same period in 2025.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Arbutus Biopharma Corp reported quarter ended March 31, 2026 results: net income For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.8, EPS income of $0.88 per basic and $0.87 per diluted common share.

Period: quarter ended March 31, 2026
Net income: For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.8
EPS: income of $0.88 per basic and $0.87 per diluted common share
Result: reported results

Exact text from the filing

Total revenue was $179.1 million for the quarter ended March 31, 2026, compared to $1.8 million for the same period in 2025.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Period: quarter ended March 31, 2026
Net income: For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.8
EPS: income of $0.88 per basic and $0.87 per diluted common share
Result: reported results

Exact text from the filing

For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.87 per diluted common share, as compared to a net loss of $24.5 million, or a loss of $0.13 per basic and diluted common share, for the quarter ended March 31, 2025.

View on SEC.gov

571 earnings releases filed in the last 30 days. Browse all earnings releases →

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR

accession 0001171843-26-003346

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.